Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease

Figures & data

Table 1 Effect of Palivizumab on RSV Outcomes

Improved	Unclear	Not Improved
RSVH in preterm, moderate-late preterm, BPD and CHD infants^Citation36,Citation41–45	Effect on oxygen requirement^Citation43,Citation46–49	RSV mortality^Citation41
Hospitalization from any respiratory disease in preterm and BPD infants^Citation41,Citation43	Impact on subsequent wheeze and lung function parameters^Citation55	RSV adverse events^Citation41
RSV-related ICU admission in preterm and BPD infants^Citation37	RSVH in CF patients < 2y^Citation51	RSV length of hospital stay^Citation41
ICU length of stay in hs-CHD infants^Citation50		RSV-related ICU admission in hs-CHD infants^Citation50
Mechanical ventilation duration in hs-CHD infants^Citation50		ICU length of stay in preterm and BPD infants^Citation33
RSV infection rates at 2-year follow-up in healthy preterm infants^Citation41		Rates and duration of mechanical ventilation in preterm and BPD infants^Citation37,Citation43
		Rates of mechanical ventilation in hs-CHD infants^Citation50

Notes: Summary of literature-reported effects of Palivizumab on RSV outcomes; classified as “improved”, “unclear” or “not improved”.

Abbreviations: RSV, Respiratory Syncytial Virus; RSVH, Respiratory Syncytial Virus-related Hospitalization, BPD, Bronchopulmonary Dysplasia; CHD, Congenital Heart Disease; hs-CHD, Haemodynamically-significant Congenital Heart Disease; ICU, Intensive Care Unit; CF, Cystic Fibrosis.

Simoes EA, Sondheimer HM, Top FH, et al.; The Cardiac Study Group. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr. 1998;133:492–499.

 PubMed Web of Science ®Google Scholar

Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JVA. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021;11(11):CD013757. doi:10.1002/14651858.CD013757.pub2

 PubMedGoogle Scholar

Harkensee C, Brodlie M, Embleton ND, Mckean M. Passive immunisation of preterm infants with palivizumab against RSV infection. J Infect. 2006;52(1):2–8. doi:10.1016/j.jinf.2005.08.003

 PubMed Web of Science ®Google Scholar

Sharland M, Cant A, Dagan R, et al. Manual of Childhood Infections (Oxford Specialist Handbooks in Paediatrics): The Blue Book. 4th ed. Oxford: Oxford University Press; 2016.

 Google Scholar

Oertel MD. RespiGam: an RSV immune globulin. Pediatr Nurs. 1996;22(6):525.

 PubMedGoogle Scholar

Groothuis JR. Safety of palivizumab in preterm infants 29 to 32 weeks’ gestational age without chronic lung disease to prevent serious respiratory syncytial virus infection. Eur J Clin Microbiol Infect Dis. 2003;22(7):414–417. doi:10.1007/s10096-003-0961-z

 PubMed Web of Science ®Google Scholar

Resch B, Bramreiter VS, Kurath-Koller S, et al. Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis. Eur J Clin Microbiol Infect Dis. 2017;36(6):1057–1062. doi:10.1007/s10096-016-2891-6

 PubMed Web of Science ®Google Scholar

Stiehm RE, Keller MA. Chapter 256 – passive Immunisation. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL, editors. Feigin and Cherry’s Textbook of Pediatric Infectious Diseases. 6th ed. Amazon; 2009:3401–3446.

 Google Scholar